Drug Profile


Alternative Names: inCVAX-N-dihydro-galacto-chitosan

Latest Information Update: 13 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Immunophotonics
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast cancer
  • Preclinical Malignant melanoma

Most Recent Events

  • 23 Aug 2016 Phase-II/III clinical trials in Breast cancer (Late-stage disease) in Peru (Parenteral)
  • 23 Aug 2016 Immunophotonics intends to submit IND application for inCVAX in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top